0.71Open0.71Pre Close0 Volume1 Open Interest360.00Strike Price0.00Turnover116.61%IV42.06%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.71Extrinsic Value100Contract SizeAmericanOptions Type0.0395Delta0.0018Gamma357.62Leverage Ratio-0.2010Theta0.0024Rho14.11Eff Leverage0.0349Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet